Lilly launches four-dose Zepbound KwikPen at same self-pay prices as vials
Zepbound's new multi-dose pen gives self-pay patients a month of doses in one device at the same posted price as vials, but needles are sold separately and the pen must not be shared.
Eli Lilly said Feb. 23, 2026 that the FDA approved a label expansion for Zepbound (tirzepatide) to include a four-dose KwikPen for single-patient use, a device that delivers a full month of treatment in one pen [1]. The company said the pen is available now by prescription through LillyDirect in all six Zepbound strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg [1][2].
Lilly said self-pay customers pay the same prices for the KwikPen as for its single-dose vials. That starts at $299 a month for the 2.5 mg dose and $399 a month for 5 mg [1][2]. The 7.5 mg, 10 mg, 12.5 mg and 15 mg doses are listed at $449 a month when the prescription is refilled within 45 days [2]. If the refill does not happen within that window, Lilly's posted prices for those higher doses are $499 a month for 7.5 mg and $699 a month for 10 mg, 12.5 mg and 15 mg [2].
LillyDirect lists the KwikPen as accepting select insurance or self-pay, while the single-dose vial remains self-pay only [2]. The KwikPen requires a separate pen needle purchase, and the vial requires separate needles and syringes [2]. A third option, the single-dose pen, includes its needle and is listed with an insurance price as low as $25 a month for up to a three-month prescription [2].
The labeling says the KwikPen should not be shared with other people, even if the pen needle has been changed, because of the risk of serious infection [1]. Zepbound's 2.5 mg dose is a starting dose and is not an approved maintenance dose; the recommended maintenance doses are 5 mg, 10 mg or 15 mg injected under the skin once weekly for weight reduction and long-term maintenance, and 10 mg or 15 mg for obstructive sleep apnea [1]. Zepbound contains tirzepatide and should not be used with other tirzepatide products or any GLP-1 receptor agonist medicine, according to the prescribing information [1].
Lilly said more than 1 million patients accessed its treatments through LillyDirect in 2025, and that one of every three new patients starting a branded weight management medication that year was prescribed Zepbound self-pay vials [1]. The company said LillyDirect self-pay pricing is 50% or more below the list price of other incretin (GLP-1) medicines for obesity [1].
"As part of our commitment to supporting people living with obesity in their weight management journey, we are introducing a new option with the Zepbound KwikPen, a device trusted by patients globally and in the United States for other Lilly medicines," said Ilya Yuffa, executive vice president and president of Lilly USA and Global Customer Capabilities [1].
In the SURMOUNT-1 trial, adults taking Zepbound 15 mg lost an average of 20.9% of body weight over 72 weeks, compared with 3.1% for placebo, Lilly said [1]. In SURMOUNT-5, an open-label study that Lilly describes as less rigorous and therefore less certain, people taking Zepbound lost an average of 50 pounds, or 20.2% of body weight, over 72 weeks, compared with 33 pounds, or 13.7%, for injectable Wegovy (semaglutide) [1].
Why it matters for patients
Zepbound now comes in three delivery formats in the United States: a multi-dose pen, a single-dose pen with its needle included, and a single-dose vial that requires separate needles and syringes [2]. For people paying cash, the posted monthly cost of the KwikPen matches the vial at every strength, so the difference between them is mainly how the device is handled and which supplies must be bought separately [1][2].
Because the KwikPen is listed as accepting select insurance while the vial is self-pay only, the pen may open a covered path for patients whose plans cover Zepbound, though the posted self-pay figures apply only to self-pay purchases [1][2]. Lilly also points eligible Medicare Part D patients with a KwikPen prescription for weight management to the Medicare GLP-1 Bridge program [2].
One practical limit is built into the device: it is for a single patient and must not be shared, even with a new needle [1].
What is not yet known
Whether commercial insurers will cover the KwikPen at the same copay as the single-dose pen has not been reported [1][2]. Lilly also has not disclosed prices for the KwikPen bought outside LillyDirect or a timeline for additional retail availability beyond the current prescription rollout [1][2].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.